ture in this range potently sensitise neoplastic cells to cisplatin cytotoxicity in vitro and in vivo (Meyn et al., 1980; Barlogie et al., 1980) . However, cisplatin nephrotoxicity is increased to a similar extent (Wondergem et al., 1988; Gerad et al., 1983) so that WBH offers no therapeutic gain for cisplatin.
Temperatures compatible with WBH also markedly sensitise various neoplastic cells to carboplatin cytotoxicity in vitro producing 3 to 5-fold thermal dose modifying factors (Cohen & Robin, 1987; Cohen et al., 1989a; Cohen et al., 1990a) . The degree of thermal sensitisation for carboplatin is equivalent to that for cisplatin (Cohen et al., 1989b) . Carboplatin is also much less neurotoxic and emetogenic than cisplatin (Calvert et al., 1982; Koeller et al., 1986 ) an important consideration when using a WBH device which does not require endotracheal intubation or general anaesthesia (Robins et al., 1985) . Most importantly, carboplatin produces little or no nephrotoxicity (Calvert et al., 1982; Koeller et al., 1986) even at doses used in autologous bone marrow transplantation (Nichols et al., 1988) . Thus, carboplatin appears to be an ideal agent among the platinum analogues for use with WBH (Cohen & Robin, 1987) .
A key consideration, which has not been addressed previously, is how WBH affects carboplatin's therapeutic index, i.e., the drug's relative toxicity for neoplastic vs normal cells. (Beginning with a report in this journal in 1982, only a few studies have ever addressed how WBH affects the therapeutic index of traditional chemotherapeutic agents (Honess & Bleehen, 1982 , Honess & Bleehen, 1985a , Honess & Bleenhen, 1985b ; none of these studies has involved radiant heat WBH.) Carboplatin's dose limiting toxicity is myelosuppression (Calvert et al., 1982; Koeller et al., 1986) . Therefore, in the present studies, we determined the effect of WBH and carboplatin, separately or in combination, on peripheral blood leukocyte and platelet counts as well as on the survival of leukaemic and normal bone marrow stem cells treated in vivo as measured by spleen colony formation.
For the present studies, WBH was performed as we have previously described in detail (Robins et al., 1984; Steeves et al., 1987 White blood cell and platelet counts were determined for individual animals from 20 ll tail vein blood samples using the Unopette microcollection/dilution system (Becton-Dickinson, Rutherford, NJ) and hand-held hemacytometers precisely as we have recently described (Cohen & Robins, 1990b) . Baseline leukocyte and platelet counts were determined pretreatment. Thereafter, each treatment group was divided into smaller groups of three mice. Leukocyte and platelet counts were performed every 3 to 4 days on groups of three mice in such a manner that each mouse was bled only every 6 or 7 days. Each blood count was performed in duplicate. Spleen colony formation was determined as we have previously described in detail (Flentje et al., 1984; Steeves et al., 1987) : Normal and leukaemia bearing mice (tail vein injection of 1 x 105 AKR leukaemia cells on day 1) were treated on day 4. On day 5, femoral and tibial bone marrow plugs were harvested from normal mice and spleens were harvested from leukaemia bearing animals. The cell samples were washed, resuspended and the number of nucleated cells was determined (Flentje et al., 1984; Steeves et al., 1987) . Normal and leukaemic spleen colon forming units were assayed by tail vein injection of nucleated normal marrow cells into lethally irradiated (7.5 Gray, single fraction) and nonradiated mice respectively. Spleens were removed 8 or 9 days later, fixed in Bouin's solution and then surface colonies were visually counted. Spleen colony formation was determined as the survival fraction ('SF') relative to the spleen colony formation of untreated controls cells, i.e., colony forming efficiency for cells from untreated control animals was normalised to one (see Steeves et al., 1987) . The colony forming efficiency of normal marrow stem cells was approximately 1.5 10-nucleated cells and 100 to 150 10-4 nucleated cells for splenic leukaemic cells. Figure 2 presents data from a single representative experiment which illustrates the myelosuppressive effects of carboplatin with and without WBH. These results are in quanti- In considering the above date, several points are worthy of discussion. WBH alone and carboplatin alone decrease the survival of leukaemic cells and normal marrow stem cells (Figure 1 ). This effect of WBH alone has been noted previously in AKR mice (Steeves et al., 1987) . WBH alone and carboplatin alone produce similar degrees of cytotoxicity in leukaemic and normal cells (with the absolute SF for leukaemic cells being lower; P < 0.0004). For WBH plus carboplatin the degree of chemosensitisation is greater for leukaemic cells than for normal cells (P = 0.0054). The reliability of this result is increase by the fact that it was obtained in vivo using a syngeneic model in which closely analogous neoplastic and normal cells received the same WBH-carboplatin regimen. The degree to which 41.5°C hyperthermia increased carboplatin toxicity for the AKR T cell leukaemia cells (Figure 1) is consistent with earlier carboplatin studies using the JM cell line (a human T cell acute leukaemia) in vitro at 41.8°C (Cohen & Robins, 1987) . The preferential sensitisation of the AKR leukaemia cells may relate to the 12 h doubling time of these cells (Steeves et al., 1987) in contrast to the more heterogeneous behaviour of the normal marrow stem cells of AKR mice (Robins et al., 1988) .
The peripheral blood counts in Table I provide a second measure of normal tissue toxicity which correlates closely with the NCFU results in Figure 1 . WBH alone (Table I) (Robins et al., 1990) . In contrast, radiant heat WBH by itself causes no blood count depression in man (Robins et al., 1985) . WBH does appear to affect carboplatin myelosuppression in AKR mice (Table I) but not in dogs (Page et al., 1989) or man (Robins et al., 1991) in an ongoing phase I study). These differences in toxicity may relate to methodological differences in performing WBH in these various species. For example, in man, due to increased metabolic rate, no appreciable supplemental heat is necessary to maintain the target temperature, a time at which bone marrow undergoes a unique and potentially protective (Robins et al., 1990) 0.6°C temperature decrease in large mammals (Hugander et al., 1987) . This is not the case for rodents (Robins et al., 1984) . There also are pharmacologic differences, e.g., intravenous lidocaine and thiopental as well as supplementary oxygen are given in man (Robins et al., 1985) but not in the mouse (Robins et al., 1984) .
These new data support the view that WBH enhances carboplatin cytotoxicity more for AKR leukaemia cells than for normal marrow stem cells (Figure 1) , and that WBH has relatively little effect on carboplatin-induced platelet and leukocyte count depression. These findings support the concept that WBH might increase carboplatin's therapeutic index, i.e., increase neoplastic cell killing relative to normal cell killing. Preliminary clinical observations that WBH does not alter carboplatin myelosuppression or pharmacokinetics in man, coupled with observed clinical activity (Robins et al., 1991) 
